NYR
data caveat$147M23mo
Nyrada
Biotechnology · Cardiovascular / Neurology
Developing Xolatryp for STEMI reperfusion injury (Phase 2) and NYR-BI03 for brain injury (Phase 1 completed). Dual cardiovascular + neuroprotection pipeline.
Data HealthFiling4C overdue · Dec 202580d
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.7M
Mar 2026 4C
Runway
23moSTABLE
Based on Mar 2026 4C
Market Cap
$147M
Burn Rate
$0.9M/qtr
Mar 2026 4C
Shares Outstanding
245M
Pipeline Assets
2
Latest Insight(1)
14 Apr 2026Quarterly 4CQuarterly Activities Report and Appendix 4C
Cash$6.7M·Burn$0.9M/q·OCF$-0.9M
3M Price
NYR.ASX$0.600-35.8% 3M
Low $0.485High $1.020
Pipeline Assets (2)
NYR-BI03Traumatic brain injury
Phase 1XolatrypSTEMI reperfusion injury
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
NYR-BI03
Traumatic brain injury
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
2 transactionsLast 90dNet Buy
Buys1+1 vs prior
Sells0
Buy Value$540k
warningJohn Moore bought 52d before "PROTECT-MI Phase IIa first patient dosing" ($540,000)
$540,0002026-03-09
22d before ·
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
2 approved drugs92 competitor trialsPhase 2+ · Non-ASX
Traumatic Brain Injury90 active trials
11 Ph422 Ph38 Ph2/342 Ph27 Ph1/PHASE2
Approved
Stemi Reperfusion Injury2 active trials
2 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (6)· 4 upcoming · 2 past
ConfirmedremoveMed31 Mar 2026
Expectedarrow_upwardHigh30 Apr 2026
NYR-BI03 Phase 1 brain injury final results
UpcomingExpectedMed
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High73/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 6 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
Completed catalysts
✓First Site Activated in Nyradas PROTECT-MI Phase IIa Trial· readout — subject to clinical uncertainty— This announcement reports the activation of the first clinical trial site (Nepean Hospital, NSW) for the PROTECT-MI Phase IIa trial, marking the formal launch of recruitment operations. No efficacy or outcome results are available as the trial has only just begun enrolling patients. The prior Phase I trial (48 participants) met its primary endpoint, confirming Xolatryp was safe and well-tolerated at all doses tested.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
Ph2Not Yet Recruiting
XolatrypPlacebo
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction · Reperfusion Injury · AMI +1 more
RandomizedQuadruple Blind40 Years – 75 Years
Primary endpoint Incidence of Adverse Events
Announcements(7)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities Report and Appendix 4C14 Apr 2026
expand_more543KB